A significant share of hospital presentations linked to injectable performance-enhancing drug use are infections and injection-site injuries rather than drug effects. These harms are procedural, well documented, and largely avoidable.
What the clinical literature reports
Case series from surgical and infectious disease settings describe abscesses, cellulitis, deep tissue infections and, less often, endocarditis and bloodborne virus transmission among people injecting performance-enhancing drugs. These reports frequently involve people who did not consider themselves at risk because they were not injecting recreational drugs.
The recurring contributing factors are reused needles, multi-dose vials shared between people, unsterile reconstitution of powdered peptides, poor skin preparation and injecting into the same site repeatedly.
Sterility of the product itself
Peptides sold as research chemicals arrive as lyophilised powder in vials with no assurance of sterility, and are reconstituted by the user. Bacteriostatic water inhibits bacterial growth but does not sterilise a contaminated preparation, and it does not compensate for a contaminated vial or a contaminated stopper.
Repeated entry into a vial over weeks increases contamination risk each time. Storage conditions, particularly for reconstituted peptides that require refrigeration, are a further documented failure point.
Practices that reduce risk
One sterile needle per injection, never reused, never shared, and disposed of in a sharps container. A fresh alcohol swab on the vial stopper and on the skin, each allowed to dry before proceeding.
Rotating sites to avoid repeated trauma to the same tissue, and avoiding injection into inflamed, bruised or previously infected areas. Drawing with one needle and injecting with another reduces dulling and tissue trauma.
Needle and syringe programmes in Australia supply equipment and sharps disposal without judgement, and are used by people injecting performance-enhancing drugs as well as other substances.
Recognising an infection early
Expanding redness, increasing pain rather than settling soreness, heat, hardness or a fluctuant lump, discharge, or fever any time after injecting means clinical assessment. Abscesses do not resolve with time, heat packs or antibiotics alone once established; they usually require drainage.
Fever with rigors, spreading redness, or feeling systemically unwell after injecting is urgent. Deep infections progress quickly and are far harder to treat late.
In short
- Infections and injection-site injuries are among the most common documented harms, independent of the drug used.
- Never share or reuse needles or vials; bacteriostatic water does not sterilise anything.
- Swab vial and skin, let both dry, rotate sites, and use a sharps container.
- Spreading redness, worsening pain, a hard lump or any fever means get it assessed now.
Unfamiliar terminology is defined in our glossary. How we research and grade evidence is set out in our editorial standards, and errors can be reported through corrections.
This article is educational. It is not medical advice, a dosing recommendation, or an endorsement of use. Speak with a qualified medical practitioner about your circumstances.